Collado-Chagoya R, Hernández-Romero J, Cruz-Pantoja R, Velasco-Medina A, Velázquez-Samano G, Castillo-Castillo D, Rosales-Pérez J

Language: Spanish
References: 24
Page: 144-151
PDF size: 490.12 Kb.

ABSTRACT

Background: Allergic bronchopulmonary aspergillosis is a disease resulting from a hypersensitivity reaction to the Aspergillus fungus by invading the airway. It is characterized clinically by dyspnea, wheezing, fever, malaise and brown or black expectoration, and by poor clinical response to the usual treatment prescribed to treat exacerbations in patients with chronic lung disease. Aspergillosis is considered the fourth most important fungal disease in Mexico; however, its role in asthmatic patients in our country is unknown.
Clinical case: A 60-year-old female patient, a health worker, with asthma of difficult control and a severe asthma attack; the diagnosis of allergic bronchopulmonary aspergillosis and its subsequent treatment were demonstrated.
Conclusions: Allergic bronchopulmonary aspergillosis is a disease difficult to diagnose in atopic, immunosuppressed or cystic fibrosis patients that all physicians treating patients who do not respond to standard treatment should suspect.

REFERENCES

1. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135: 805-826. doi. 10.1378/chest.08-2586.

2. Hogan C, Denning DW. Allergic bronchopulmonary aspergillosis and related allergic syndromes. Semin Respir Crit Care Med 2011; 32: 682-92. doi. 10.1055/s-0031-1295716.

3. Arenas-Guzmán R. Arenas-Guzmán R, editor. Micología médica ilustrada, 5a ed. Nueva York: Mc Graw Hill 2014; capítulo 23.

4. Maurya V, Gugnani HC, Sarma PU, Madan T, et al. Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest 2005; 127: 1252-9. doi. 10.1378/chest.127.4.1252.

5. Knutsen AP. Genetic and respiratory tract risk factors for aspergillosis: ABPA and asthma with fungal sensitization. Med Mycol 2006; 44 (Suppl. 1): 61-70. doi. 10.1080/13693780600789178.

6. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 2013; 51: 361-70. doi. 10.3109/13693786.2012.738312.

7. Chauhan B, Santiago L, Hutcheson PS, Schwartz HJ, et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2000; 106: 723-9. doi. 10.1067/mai.2000.109913.

8. Kurup VP. Immunology of allergic bronchopulmonary aspergillosis. Indian J Chest Dis Allied Sci 2000; 42: 225-37.

9. Park SJ, Mehrad B. Innate immunity to Aspergillus species. Clin Microbiol Rev 2009; 22: 535-51. doi. 10.1128/ CMR.00014-09.

10. Gibson PG, Wark PAB, Simpson JL, Meldrum C, et al. Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis. Eur Respir J 2003; 21: 582-8. doi. 10.1183/09031936.03.00001803.

11. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002; 121: 1988-1999. doi. 10.1378/chest.121.6.1988.

12. Shah A, Panjabi C. Allergic aspergillosis of the respiratory tract. Eur Respir Rev 2014; 23: 8-29. doi. 10.1183/09059180.00007413.

13. Agarwal R, Khan A, Garg M, Aggarwal AN, et al. Chest radiographic and computed tomographic manifestations in allergic bronchopulmonary aspergillosis. World J Radiol 2012; 4: 141-50. doi. 10.4329/wjr.v4.i4.141.

14. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977; 86: 405-14. doi. 10.7326/0003-4819-86-4-405.

15. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110: 685-92. doi. 10.1067/ mai.2002.130179.

16. Stevens DA, Moss RB, Kurup VP, Knutsen AP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 (Suppl. 3): S225-264. doi. 10.1086/376525.

17. Agarwal R, Chakrabarti A, Shah A, Gupta D, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850-73. doi. 10.1111/cea.12141.

18. Fink JN. Therapy of allergic bronchopulmonary aspergillosis. Indian J Chest Dis Allied Sci 2000; 42: 221-4.

19. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342: 756-762. doi: 10.1056/NEJM200003163421102.

20. Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; 2004 (3): CD001108. doi. 10.1002/14651858.CD001108.pub2.

21. Tillie-Leblond I, Germaud P, Leroyer C, Tétu L, et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 2011; 66: 1254-6. doi. 10.1111/j.1398- 9995.2011.02599.x.

22. Perez-de-Llano LA, Vennera MC, Parra A et al. Effects of omalizumab in Aspergillus-associated airway disease. Thorax 2011; 66: 539-40. doi. 10.1136/thx.2010.153312.

23. Hayes D Jr, Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 2010; 45: 1145-8. doi. 10.1002/ppul.21300.

24. Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011; 105: 946-9. doi. 10.1016/j. rmed.2011.01.009.